Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

JNJ

Johnson & Johnson

Jan 22 • 09:51AM ET

142.82

Dollar change -5.33
Percentage change -3.60	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: LLY PFE MRK AMGN BMY NVS ABBV GSK AZN MDT

| Held by: VTI VOO SPY IVV VTV XLV VIG VYM DGRO IWD

Scroll to Statements

Index	DJIA, S&P 500	P/E	23.61	EPS (ttm)	6.05	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	-1.33%
Market Cap	343.86B	Forward P/E	12.88	EPS next Y	11.08	Insider Trans	-0.16%	Shs Float	2.40B	Perf Month	-1.33%
Income	14.68B	PEG	3.81	EPS next Q	2.65	Inst Own	72.77%	Short Float	0.68%	Perf Quarter	-13.51%
Sales	87.69B	P/S	3.92	EPS this Y	5.54%	Inst Trans	0.79%	Short Ratio	2.06	Perf Half Y	-7.40%
Book/sh	29.14	P/B	4.90	EPS next Y	5.24%	ROA	8.58%	Short Interest	16.46M	Perf Year	-11.67%
Cash/sh	8.43	P/C	16.94	EPS next 5Y	6.20%	ROE	20.89%	52W Range	140.68 - 168.85	Perf YTD	-1.24%
Dividend Est.	5.11 (3.58%)	P/FCF	16.58	EPS past 5Y	-0.27%	ROI	14.47%	52W High	-15.42%	Beta	0.51
Dividend TTM	4.91 (3.44%)	Quick Ratio	0.79	Sales past 5Y	1.46%	Gross Margin	68.67%	52W Low	1.52%	ATR (14)	2.62
Dividend Ex-Date	Feb 18, 2025	Current Ratio	1.03	EPS Y/Y TTM	15.10%	Oper. Margin	24.60%	RSI (14)	41.31	Volatility	1.57% 1.53%
Employees	131900	Debt/Eq	0.51	Sales Y/Y TTM	-8.03%	Profit Margin	16.75%	Recom	2.23	Target Price	172.53
Option/Short	Yes / Yes	LT Debt/Eq	0.45	EPS Q/Q	-43.91%	Payout	84.93%	Rel Volume	3.72	Prev Close	148.15
Sales Surprise	0.40%	EPS Surprise	2.43%	Sales Q/Q	5.27%	Earnings	Jan 22 BMO	Avg Volume	7.97M	Price	142.82
SMA20	-1.39%	SMA50	-4.03%	SMA200	-7.09%	Trades		Volume	3,000,724	Change	-3.60%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$166
Nov-15-24	Initiated	Wolfe Research	Outperform	$190
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183
Mar-02-22	Resumed	BofA Securities	Neutral	$185

Show Previous Ratings

Today 09:36AM	J&J, Procter & Gamble, United Airlines: Earnings movers (Yahoo Finance Video)
09:09AM	Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth (Barrons.com)
08:25AM	J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short (Investopedia)
08:21AM	Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook (Benzinga)
07:34AM	Johnson & Johnson Earnings Narrowly Top But Dow Giant's Sales Guidance Light (Investor's Business Daily)
07:30AM	Loading…
07:30AM	Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates (Zacks)
06:29AM	Johnson & Johnson: Q4 Earnings Snapshot (Associated Press Finance)
06:23AM	J&J beats quarterly sales and profit estimates on cancer drug sales (Reuters)
06:20AM	Johnson & Johnson Reports Q4 and Full-Year 2024 Results (Business Wire)
Jan-21-25 09:46PM	Jim Cramer on Johnson & Johnson (JNJ): 'Make Good Money Just By Reinvesting Their Juicy Dividends' (Insider Monkey)
07:00PM	P&G earnings, mortgage applications: What to Watch (Yahoo Finance Video)
11:57AM	FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression (Benzinga)
11:42AM	J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care (GuruFocus.com)
08:00AM	SPRAVATO (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression (PR Newswire)
06:01AM	The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value (GuruFocus.com)
06:00AM	Loading…
06:00AM	Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever. (Motley Fool)
05:34AM	Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025? (Motley Fool)
04:17AM	3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever (Motley Fool)
Jan-20-25 02:30PM	Why Johnson & Johnson (JNJ) Is the Best Soaps and Cleaning Materials Stock to Invest In (Insider Monkey)
09:54AM	What Analysts Think of Johnson & Johnson Stock Ahead of Earnings (Investopedia)
Jan-19-25 01:00PM	Why Intra-Cellular Therapies, Inc. (ITCI) Dominated Last Weeks Rally (Insider Monkey)
12:33PM	Jim Cramer on Johnson & Johnson (JNJ): 'Things Are Not Working Their Way' (Insider Monkey)
07:41AM	Trump's inauguration looms as earnings season rolls on: What to know this week (Yahoo Finance)
05:00AM	What To Expect in the Markets This Week (Investopedia)
Jan-18-25 07:02PM	Is Johnson & Johnson (JNJ) the Best Cheap Stock to Buy for 2025? (Insider Monkey)
05:01PM	Count on Dividend King Pepsi (PEP) for Stability in a Volatile Market (TipRanks)
12:31PM	Tariff threats, drug pricing will be 2 key pharma issues during Trump's first year (Yahoo Finance)
10:10AM	Why Is Cliff Asness Bullish On Johnson & Johnson (JNJ)? (Insider Monkey)
06:18AM	3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond (Motley Fool)
Jan-17-25 10:24AM	Netflix's Strategic Shift Faces Test As Streaming Giant, Dow Stocks Head Into Earnings (Investor's Business Daily)
07:38AM	Loading…
07:38AM	Mega M&A at JP Morgan Conference 2025 is biopharma M&A poised for a rebound? (Pharmaceutical Technology)
Jan-16-25 05:45PM	Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know (Zacks)
09:15AM	Insights Into Johnson & Johnson (JNJ) Q4: Wall Street Projections for Key Metrics (Zacks)
09:11AM	RYBREVANT® plus chemotherapy approved in Canada as first and only targeted treatment to reduce risk of disease progression or death by more than half in second-line EGFR-mutated advanced lung cancer (PR Newswire)
02:10AM	By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years (Pharma Voice)
Jan-15-25 11:00AM	J&J's AAA Rating in Jeopardy as Acquisition Sparks Debt Concerns (GuruFocus.com)
10:16AM	J&Js Top Rating at Risk Because of Intra-Cellular Deal (Bloomberg)
10:09AM	Analyst Report: Johnson & Johnson (Morningstar Research)
08:00AM	New Drug Application initiated with U.S. FDA for TAR-200, the first and only intravesical drug releasing system for patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (PR Newswire)
06:45AM	J&J files a potential blockbuster; Lykos shakes up its board (BioPharma Dive)
05:36AM	Aggressive protection of Stelara may indicate J&Js immunology strategy (Pharmaceutical Technology)
05:10AM	Got $200? 2 Dividend Stocks to Buy and Hold Forever (Motley Fool)
Jan-14-25 01:33PM	Johnson & Johnson (JNJ) Among the Best Dividend Kings to Buy Now (Insider Monkey)
12:13PM	J&J to leverage Intra-Cellular Therapies neurology portfolio (Pharmaceutical Technology)
10:24AM	The Hottest Ticket Across Corporate America: Trumps Inauguration (The Wall Street Journal)
09:53AM	Why Intra-Cellular (ITCI) Led the Monday Upsurge? (Insider Monkey)
09:00AM	Is Trending Stock Johnson & Johnson (JNJ) a Buy Now? (Zacks)
08:35AM	Oric Pharmaceuticals announces clinical supply agreement with Janssen (TipRanks)
06:01AM	Unlocking Intrinsic Value: Analysis of Johnson & Johnson (GuruFocus.com)
05:51AM	ITCI Stock Surges 34% as J&J Reveals $14.6 Billion Acquisition Plan (GuruFocus.com)
02:06AM	Analyst Report: Johnson & Johnson (Morningstar Research)
Jan-13-25 06:18PM	Asian Shares Look Shaky as Fed Rate-Cut Hopes Dim: Markets Wrap (Bloomberg)
04:47PM	JPMorgan Healthcare Conference: AI, billion-dollar deals (Yahoo Finance Video)
04:19PM	J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug (Investor's Business Daily)
04:06PM	Healthcare M&A poised for a rebound in 2025 (Yahoo Finance Video)
03:13PM	Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal (The Wall Street Journal)
12:02PM	Is Johnson & Johnson (JNJ) the Most Reliable Dividend Stock to Buy According to Hedge Funds? (Insider Monkey)
10:57AM	Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal (Barrons.com)
10:30AM	J&J buys Intra-Cellular in $14.6 billion deal, delving further into central nervous system disorders (Associated Press Finance)
10:15AM	Intra-Cellular Therapies Soars 32% With Johnson & Johnson's $14.6B Acquisition (GuruFocus.com)
10:14AM	Johnson & Johnson Makes Biopharmaceutical Splash with $14.6B Intra-Cellular Deal (Design & Development Today)
09:09AM	Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal (Investor's Business Daily)
08:49AM	Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B (Investopedia)
08:49AM	Intra-Cellular Therapies Stock Pops as Johnson and Johnson Buys Firm for $14.6B (Investopedia)
08:35AM	Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular (Barrons.com)
07:45AM	Update: Johnson & Johnson acquires Intra-Cellular Therapies (Pharmaceutical Technology)
07:45AM	Johnson & Johnson in talks to acquire Intra-Cellular Therapies (Pharmaceutical Technology)
06:37AM	J&J doubles down on neurological drugs with $14.6 billion Intra-Cellular deal (Reuters)
06:32AM	Johnson and Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. (GlobeNewswire)
06:30AM	Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc. (Business Wire)
06:09AM	2 Beaten-Down Dividend Stocks to Buy in 2025 (Motley Fool)
05:55AM	This Stock Is Soaring Amid Johnson & Johnson Takeover Report (Barrons.com)
04:59AM	Johnson & Johnson MedTechs Dual Energy Catheter gains CE mark approval (Medical Device Network)
Jan-10-25 04:53PM	Cramer on Johnson & Johnson (JNJ): A Value Trap Amid Lawsuits and Setbacks (Insider Monkey)
09:00AM	4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025 (Motley Fool)
04:51AM	2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid (Motley Fool)
Jan-09-25 12:00PM	Contineum concludes enrolment in Phase II multiple sclerosis therapy trial (Clinical Trials Arena)
08:04AM	Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravis (PR Newswire)
06:48AM	Johnson & Johnson MedTech pauses Varipulse rollout in US (Medical Device Network)
Jan-08-25 05:23PM	S+P 500 Gains and Losses Today: eBay Soars as Meta Permits Facebook Marketplace Listings (Investopedia)
04:07PM	J&J Falls While Boston Scientific, Medtronic Pop After Strokes Sideline A Key Product (Investor's Business Daily)
10:34AM	J&J pauses Varipulse PFA cases in US (MedTech Dive)
08:00AM	Johnson and Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease (PR Newswire)
08:00AM	Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease (PR Newswire)
07:59AM	Johnson & Johnson (JNJ): A Bull Case Theory (Insider Monkey)
05:44AM	J&J reports positive topline outcomes from Phase III NSCLC combo therapy trial (Clinical Trials Arena)
Jan-07-25 05:45PM	Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors (Zacks)
11:14AM	J&J Says Lung Cancer Combo Improves Survival More Than Standard of Care (Bloomberg)
08:00AM	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show statistically significant and clinically meaningful improvement in overall survival versus osimertinib (PR Newswire)
06:12AM	J&J says cancer drug combination showed survival benefit over Tagrisso (BioPharma Dive)
06:01AM	Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson (GuruFocus.com)
03:00AM	Subcutaneous options offer convenience for patients and a valuable window for drugmakers (Pharma Voice)
Jan-06-25 07:00AM	How Are Companies Using AI Agents? Heres a Look at Five Early Users of the Bots (The Wall Street Journal)
03:00AM	4 closely watched FDA approval dates in 2025 from J&J, Novo and more (Pharma Voice)
Jan-02-25 07:59PM	The Descent of an Army Vet Turned Corporate Consultant Named in the New Years Attack (The Wall Street Journal)
04:22PM	Neumora Therapeutics Stock Crashes 81% After Depression Drug Flops (Investor's Business Daily)
11:11AM	Johnson & Johnson Declares Dividend, Short Interest Declines (GuruFocus.com)
08:00AM	Johnson and Johnson Announces Quarterly Dividend for First Quarter 2025 (Business Wire)
08:00AM	Johnson & Johnson Announces Quarterly Dividend for First Quarter 2025 (Business Wire)
06:37AM	Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson (GuruFocus.com)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WEINBERGER MARK A	Director	Dec 12 '24	Buy	147.22	1,000	147,220	1,000	Dec 12 05:27 PM
Hait William	Former Officer	Dec 04 '24	Proposed Sale	149.90	25,742	3,858,598		Dec 04 01:25 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '24	Option Exercise	0.00	22,255	0	22,561	May 03 04:31 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Mar 13 '24	Sale	162.16	8,891	1,441,765	15,043	Mar 13 04:36 PM
JOHNSON & JOHNSON	10% Owner	Feb 29 '24	Option Exercise	0.72	3,855	2,792	4,103,430	Mar 06 03:42 PM
JOHNSON & JOHNSON	10% Owner	Feb 16 '24	Sale	25.81	3,725	96,142	4,099,575	Mar 06 03:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '24	Option Exercise	0.00	651	0	82,599	Feb 15 04:53 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '24	Option Exercise	0.00	1,780	0	69,663	Feb 15 04:53 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '24	Option Exercise	0.00	1,302	0	155,517	Feb 15 04:53 PM
Swanson James D.	EVP, CIO	Feb 13 '24	Option Exercise	0.00	447	0	14,765	Feb 15 04:53 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '24	Option Exercise	0.00	499	0	13,290	Feb 15 04:53 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 13 '24	Option Exercise	0.00	925	0	112,550	Feb 15 04:53 PM
Hait William	See Remarks	Feb 13 '24	Option Exercise	0.00	834	0	39,074	Feb 15 04:53 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '24	Option Exercise	0.00	3,470	0	364,809	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '24	Option Exercise	0.00	408	0	24,143	Feb 15 04:53 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '24	Option Exercise	0.00	651	0	8,576	Feb 15 04:53 PM
Decker Robert J	VP Corporate Controller	Feb 13 '24	Option Exercise	0.00	313	0	19,059	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 12 '24	Option Exercise	0.00	4,701	0	25,081	Feb 14 06:36 PM
Hait William	See Remarks	Feb 12 '24	Option Exercise	0.00	8,932	0	42,316	Feb 14 06:36 PM
Wolk Joseph J	Exec VP, CFO	Feb 12 '24	Option Exercise	0.00	25,835	0	78,699	Feb 14 06:36 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 12 '24	Option Exercise	0.00	2,859	0	8,959	Feb 14 06:36 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 12 '24	Option Exercise	0.00	26,202	0	167,618	Feb 14 06:36 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 12 '24	Option Exercise	0.00	14,960	0	118,644	Feb 14 06:36 PM
Swanson James D.	EVP, CIO	Feb 12 '24	Option Exercise	0.00	5,456	0	16,013	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 12 '24	Option Exercise	0.00	36,618	0	377,239	Feb 14 06:36 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 12 '24	Option Exercise	0.00	5,736	0	15,678	Feb 14 06:36 PM
Decker Robert J	VP Corporate Controller	Feb 12 '24	Option Exercise	0.00	1,912	0	19,269	Feb 14 06:36 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 12 '24	Option Exercise	0.00	13,813	0	89,014	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 09 '24	Option Exercise	90.44	130,969	11,844,836	439,283	Feb 13 05:18 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Option Exercise	90.44	59,397	5,371,865	200,813	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 08 '24	Option Exercise	0.00	3,739	0	143,329	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Sale	156.27	59,397	9,281,969	141,416	Feb 12 07:25 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 08 '24	Option Exercise	0.00	5,225	0	310,583	Feb 12 07:25 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 08 '24	Option Exercise	0.00	1,971	0	67,905	Feb 12 07:25 PM
Wolk Joseph J	Exec VP, CFO	Feb 08 '24	Option Exercise	0.00	3,686	0	53,911	Feb 12 07:25 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 08 '24	Option Exercise	0.00	979	0	6,463	Feb 12 07:24 PM
Swanson James D.	See Remarks	Feb 08 '24	Option Exercise	0.00	1,868	0	11,111	Feb 12 07:24 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 08 '24	Option Exercise	0.00	1,964	0	10,943	Feb 12 07:24 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 08 '24	Option Exercise	0.00	2,135	0	104,465	Feb 12 07:24 PM
Hait William	See Remarks	Feb 08 '24	Option Exercise	0.00	3,059	0	34,497	Feb 12 07:24 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 08 '24	Option Exercise	0.00	1,880	0	21,083	Feb 12 07:24 PM
Decker Robert J	VP Corporate Controller	Feb 08 '24	Option Exercise	0.00	655	0	17,572	Feb 12 07:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience